Bracco's SonoRx Is First Oral Contrast Agent For Upper Abdominal Imaging
This article was originally published in The Gray Sheet
Bracco Diagnostics' SonoRx, the first oral contrast agent for ultrasound imaging, will be available by the end of the year, the company said following its Oct. 29 FDA approval. SonoRx is intended to reduce gas shadowing during upper abdominal ultrasound procedures, a problem that can obscure the radiologist's view regardless of the type of ultrasound equipment used.
You may also be interested in...
The Pink Sheet explains the procedures underpinning the UK’s emergency use authorization of the Pfizer/BioNTech COVID-19 vaccine.
The US Food and Drug Administration posted two device-related closeout letters in November.
Jazz and PharmaMar need to see what further data will be needed to convert their FDA authorization into a full approval following disappointing results in the ATLANTIS Phase III trial.